1. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.
- Author
-
Fujiki, Fumihiro, Morimoto, Soyoko, Nishida, Yuya, Tanii, Satoe, Aoyama, Nao, Inatome, Miki, Inoue, Kento, Katsuhara, Akiko, Nakajima, Hiroko, Nakata, Jun, Nishida, Sumiyuki, Tsuboi, Akihiro, Oka, Yoshihiro, Oji, Yusuke, Sogo, Shinji, and Sugiyama, Haruo
- Subjects
T cells ,PEPTIDES ,CELL lines ,AMINO acids ,CLINICAL medicine - Abstract
CD4
+ T cells that recognize antigenic peptides presented on HLA class II are essential for inducing an optimal anti-tumor immune response, and adoptive transfer of tumor antigen-specific TCR-transduced CD4+ T cells with high responsiveness against tumor is a promising strategy for cancer treatment. Whereas a precise evaluation method of functional avidity, an indicator of T cell responsiveness against tumors, has been established for HLA class I-restricted TCRs, it remains unestablished for HLA class II-restricted TCRs. In this study, we generated a novel platform cell line, CD4-2D3, in which GFP reporter was expressed by NFAT activation via TCR signaling, for correctly evaluating functional avidity of HLA class II-restricted TCRs. Furthermore, using this platform cell line, we succeeded in maturating functional avidity of an HLA class II-restricted TCR specific for a WT1-derived helper peptide by substituting amino acids in complementarity determining region 3 (CDR3) of the TCR. Importantly, we demonstrated that transduction of an avidity-maturated TCR conferred strong cytotoxicity against WT1-expressing leukemia cells on CD4+ T cells, compared to that of its original TCR. Thus, CD4-2D3 cell line should be useful not only to evaluate TCR functional avidity in HLA class II-restricted TCRs but also to screen appropriate TCRs for clinical applications such as cancer immunotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF